Doctronic Raises $40 Million in Series B Funding
Doctronic, a New York City-based AI healthcare company, has successfully raised $40 million in a Series B funding round. The round was led by Abstract Ventures, with participation from Lightspeed Venture Partners, Union Square Ventures, Seven Stars, Tusk Ventures, and Mantis Venture Partners. Doctronic is renowned for being the first AI system legally authorized to practice medicine in the United States, offering free personalized health insights and connecting users to licensed providers.
Leadership and Vision
Doctronic was founded in 2023 by Matt Pavelle, who serves as Co-founder and Co-CEO, and Adam Oskowitz, also a Co-founder. The leadership team has been instrumental in driving the company's mission to integrate AI effectively into healthcare services. Pavelle noted: "Doctronic proved what we believed from the start: AI can deliver better healthcare outcomes at scale."
Use of Funds
The newly secured funds will support Doctronic's efforts to expand its partnerships with hospital systems, academic institutions, digital health platforms, and insurance payers. Additionally, the company plans to extend its services into pediatric care, where demand is growing. The funding will also fuel continued product development and geographic expansion, with ongoing discussions to extend AI-powered prescription services beyond Utah.
Recent Growth and Milestones
In recent months, Doctronic has experienced significant growth. The platform now serves over 300,000 weekly users and has reported a 15x increase in revenue to an eight-figure annualized amount since its Series A round. A key milestone for the company occurred in December 2025, when it became the first AI-native platform authorized to autonomously renew prescriptions under Utah’s AI Learning Lab regulatory sandbox. The system currently supports prescription renewals for 190 medications, incorporating safety protocols and escalation to licensed physicians when necessary.
Future Outlook
Doctronic's innovative approach positions it as a leader in AI-powered healthcare. By maintaining a robust infrastructure that integrates patient records, medication histories, and drug interaction data, the company is setting a new standard for primary care delivery. With the latest funding, Doctronic is well-positioned to continue its expansion and enhance its service offerings, potentially transforming the healthcare landscape in the United States and beyond.